These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8821615)

  • 1. Effect of NCCLS, SFM, and DIN breakpoints upon the incidence of co-amoxiclav resistance in Escherichia coli.
    Durodia J; Simpson I
    J Antimicrob Chemother; 1995 Dec; 36(6):1105-6. PubMed ID: 8821615
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of following National Committee for Clinical Laboratory Standards and Deutsche Industrie Norm-Medizinische Mikrobiologie guidelines, country of isolate origin, and site of infection on susceptibility of Escherichia coli to amoxicillin-clavulanate (Augmentin).
    Simpson I; Durodie J; Knott S; Shea B; Wilson J; Machka K
    J Clin Microbiol; 1998 May; 36(5):1361-5. PubMed ID: 9574706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of beta-lactamases produced by cephalothin-susceptible Escherichia coli clinical isolates resistant to co-amoxiclav and ticarcillin-clavulanic acid. The CERIB Study Group.
    Chardon H; Farzaneh S; Labia R; Jarlier V; Nicolas MH; Paul G; Poyart C; Sirot D; Sirot J
    J Antimicrob Chemother; 1995 Jul; 36(1):267-9. PubMed ID: 8537279
    [No Abstract]   [Full Text] [Related]  

  • 4. Resistance to amoxicillin/clavulanate in Escherichia coli.
    Colaert J
    Acta Clin Belg; 1992; 47(5):353-4. PubMed ID: 1334324
    [No Abstract]   [Full Text] [Related]  

  • 5. Resistance to amoxicillin/clavulanate in Escherichia coli.
    Glupczynski Y; Mac Gillavry G; Yourassowsky E
    Acta Clin Belg; 1992; 47(5):354-5. PubMed ID: 1334325
    [No Abstract]   [Full Text] [Related]  

  • 6. Development of resistance to ceftazidime and co-amoxiclav in Pseudomonas pseudomallei.
    Dance DA; Wuthiekanun V; Chaowagul W; Suputtamongkol Y; White NJ
    J Antimicrob Chemother; 1991 Aug; 28(2):321-4. PubMed ID: 1723404
    [No Abstract]   [Full Text] [Related]  

  • 7. Lack of increase in resistance to quinolones in general practice isolates of Escherichia coli.
    Weber P; Plaisance JJ; Mancy C
    J Antimicrob Chemother; 1994 Jul; 34(1):187-8. PubMed ID: 7961211
    [No Abstract]   [Full Text] [Related]  

  • 8. Activity of amoxycillin/clavulanic acid against Escherichia coli in vivo--correction.
    Beale AS
    J Antimicrob Chemother; 1992 Jul; 30(1):108. PubMed ID: 1429330
    [No Abstract]   [Full Text] [Related]  

  • 9. Reduced susceptibility to co-amoxiclav in Escherichia coli, Salmonella typhimurium and Klebsiella pneumoniae isolated in Romania between 1985 and 1993.
    Espinasse F; Gheorghiu R; Poiata A; Labia R; Nicolas-Chanoine MH
    J Antimicrob Chemother; 1997 Jan; 39(1):103-6. PubMed ID: 9044036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Problems associated with susceptibility testing of co-amoxiclav: an interpretive solution.
    Alós JI
    J Antimicrob Chemother; 1994 Jan; 33(1):183. PubMed ID: 8179721
    [No Abstract]   [Full Text] [Related]  

  • 11. Quality control parameters for broth microdilution susceptibility testing of amoxicillin and amoxicillin-clavulanic acid.
    Barry AL; Allen SD; Fuchs PC; Jorgensen JH; Pfaller MA
    Eur J Clin Microbiol Infect Dis; 1994 Feb; 13(2):186-8. PubMed ID: 8013498
    [No Abstract]   [Full Text] [Related]  

  • 12. A review of the microbiology of amoxycillin/clavulanic acid over the 15 year period 1978-1993.
    Rolinson GN
    J Chemother; 1994 Oct; 6(5):283-318. PubMed ID: 7861195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli.
    Stapleton P; Wu PJ; King A; Shannon K; French G; Phillips I
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2478-83. PubMed ID: 8585729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of enteric pathogens to amoxicillin and clavulanate-potentiated amoxicillin.
    Mégraud F; Gavinet A
    Chemioterapia; 1987 Jun; 6(2 Suppl):75-6. PubMed ID: 3334666
    [No Abstract]   [Full Text] [Related]  

  • 15. Activity of clavulanate combinations against TEM-1 beta-lactamase-producing Escherichia coli isolates obtained in 1982 and 1989.
    Seetulsingh PS; Hall LM; Livermore DM
    J Antimicrob Chemother; 1991 Jun; 27(6):749-59. PubMed ID: 1938685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of extended broad-spectrum beta-lactamases in Enterobacteriaceae in four French hospitals.
    Legrand P; Fournier G; Buré A; Jarlier V; Nicolas MH; Decré D; Duval J; Philippon A
    Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):527-9. PubMed ID: 2504594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of resistance in bacteria interacting with subinhibitory antibiotic concentrations].
    Cokça F; Altay G
    Mikrobiyol Bul; 1992 Oct; 26(4):333-7. PubMed ID: 1435363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The antimicrobial activity of Augmentin (amoxicillin/clavulanic acid) compared to other antibacterial agents].
    Zubkov MN; Nonikov VE; Gugutsidze EN; Sutormina TM; Makarova OV
    Antibiot Khimioter; 1992 Sep; 37(9):34-6. PubMed ID: 1444669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-lactamase inhibitors and Acinetobacter spp.
    Eng RH; Smith SM; Cherubin CE
    J Antimicrob Chemother; 1990 Sep; 26(3):449-51. PubMed ID: 2172200
    [No Abstract]   [Full Text] [Related]  

  • 20. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .
    Livermore DM; Seetulsingh P
    J Antimicrob Chemother; 1991 Jun; 27(6):761-7. PubMed ID: 1669013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.